Clinical Trial Update: A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH ) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating HP515 for non-alcoholic fatty liver disease, including potential nonalcoholic steatohepatitis, is currently recruiting. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• HP515

Snippet

Sponsor: Hinova Pharmaceuticals Inc. | Conditions: NAFLD (Non-alcoholic Fatty Liver Disease) | Phase 2 | Status: RECRUITING